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Primary percutaneous coronary interventionBackground:Rapid inhibition of platelet function is critical in patients referred for primary percutaneous coronary
intervention (PCI) to prevent stent thrombosis. We sought to determine the antiplatelet effects of two
clopidogrel high loading dose (LD) strategies on platelet reactivity in patients presentingwith ST-elevationmyo-
cardial infarction (STEMI).
Methods: Patients referred for primary PCIwere randomly assigned to one of two clopidogrel LDs initiated before
catheterization: 600 mg vs. 600/600 mg (second dose 3 h after ﬁrst LD). Platelet function testing was performed
at baseline, and at 1, 2, 4, 6, 24, and 48h after the initial LDusing the VerifyNowdevice. The primary endpointwas
the proportion of patientswith high platelet reactivity (HPR) at 24 h deﬁned as a P2Y12 reaction unit (PRU)mea-
surement N208.
Results: Fifty-four patientswere assigned to clopidogrel as a single 600mgLD (n=27) or as a 600/600mgdouble
LD (n= 27). The proportion of patients with HPR at 24 h was recorded in 44.0% assigned to the 600 mg LD and
24.0% of patients assigned to 600/600mg LD, p=0.23. Themean PRUat 24 hwas 191±102 in the 600mg group
and 152± 94 in the 600/600mg group, p= 0.16. There was no difference at all time points in HPR, and inmean
PRUs between the LD regimens.
Conclusions: High platelet reactivity persisted at 24 h in a signiﬁcant proportion of patients referred for primary
PCI regardless of two clopidogrel high LD strategies. These results may have implications regarding the risk of
early stent thrombosis in STEMI patients treated with clopidogrel.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Achieving rapid inhibition of platelet function is critical in patients
with ST-elevation myocardial infarction (STEMI) referred for primary
percutaneous coronary intervention (PCI) to prevent early stent throm-
bosis. It has therefore become standard practice to prescribe to these pa-
tients dual oral antiplatelet therapy consisting of aspirin and a P2Y12
adenosine diphosphate receptor inhibitor prior to cardiac catheteriza-
tion. In the last decade clopidogrel has been used extensively in this
setting. In the last 5 years, use of ticagrelor has gradually increased in
STEMI patients. However, clopidogrel remains the drug of choice in pa-
tients who either cannot afford or develop dyspnea secondary to
ticagrelor.).
. This is an open access article underSeveral studies link recurrent ischemic events after PCI to high plate-
let reactivity (HPR) [1–7]. The mechanisms leading to poor clopidogrel
effects are likely multifactorial [8]. Small studies have shown that faster
and higher degree of platelet inhibition can be achieved with a 600 mg
loading dose (LD) of clopidogrel as compared to a 300 mg LD [9,10].
Clinical studies have conﬁrmed that a 600mg LDprovides superior ben-
eﬁt over a 300 mg LD in patients undergoing urgent PCI [11,12]. More-
over, pharmacodynamic studies evaluating higher clopidogrel LDs in
relatively stable patients suggest that 900mg and 1200mgmay achieve
faster and greater inhibition of platelet activity [9,13]. However, most of
the studies have beendone in relatively stable patients and data relating
to STEMI patients is very limited. Indeed, the pharmacokinetic and
pharmacodynamic properties of clopidogrel may differ considerably in
STEMI patients because of altered absorption and metabolism of the
drug in conjunctionwith amore inﬂammatory andmore prothrombotic
milieu, factors that may impact on HPR [14–16]. Accordingly, we de-
signed a pilot study to evaluate the effect of two high LDs of clopidogrelthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
8 K. Singh et al. / Clinical Trials and Regulatory Science in Cardiology 10 (2015) 7–12on HPR measured at speciﬁc time points in STEMI patients referred for
primary PCI.
2. Methods
2.1. Trial design
The CArdiovascular Percutaneous Intervention TriAL Group (CAPI-
TAL) LOADwas a prospective, randomized pilot study designed to eval-
uate HPR with the use of high LDs of clopidogrel in STEMI patients
referred for primary PCI: speciﬁcally, the study compared a LD of
600 mg vs. a double 600/600 mg LD. The study was conducted at the
University of Ottawa Heart Institute, the center responsible for primary
PCI for the region.
2.2. Patient selection
Patientswere eligible for enrollment if they presentedwithin 12 h of
the onset of ischemic chest discomfort of at least 30 min duration and
having at least 1 mm (0.1 mV) ST-elevation in 2 or more contiguous
leads on a standard 12-lead ECG. We excluded patients who presented
with: active bleeding, stroke within 90 days, intracranial bleeding at
any time, major surgery or trauma within 6 weeks, PCI within 30 days,
ﬁbrinolytic agents within 7 days, glycoprotein IIb/IIIa inhibitors within
7 days, a coagulation disorder, current warfarin or clopidogrel therapy,
known renal impairment (creatinine clearance rate of b30 ml/min),
and cardiogenic shock. We also excluded patients following coronary
angiography who did not have evidence supporting STEMI, who re-
ceived glycoprotein IIb/IIIb inhibitors during the PCI, who required im-
mediate bypass surgery or were found to have severe anemia
preventing measurement of platelet reactivity with the point of care
test. The protocol was approved by the institutional review board and
all patients provided informed consent.
Patients were randomly assigned to a clopidogrel LD administered
on an open-label basis before cardiac catheterization: patients received
either a single LD 600 mg or a double LD 600/600 mg (second dose 3 h
after the ﬁrst LD for a total of 1200 mg). In all cases PCI was performed
immediately after the initial LD without delay related to a second LD.
Before catheterization, all patients received 160 mg of chewable as-
pirin, and 60 U/kg of intravenous unfractionated heparin up to a maxi-
mum dose of 4000 U. Bivalirudin was used as anticoagulant during the
PCI procedure administered as an initial bolus of 0.75 mg/kg intrave-
nously followed by an infusion of 1.75 mg/kg/h. Upon completion of
the PCI procedure the dose was adjusted to 0.25 mg/kg/h infusion for
two hours and then completely stopped. Coronary angiography was
performed using a nonionic contrast medium. On the day after the pro-
cedure patients were prescribed maintenance clopidogrel 75 mg daily
for at least one year and aspirin 81mg daily indeﬁnitely. Serum creatine
kinase and troponins were assessed on admission and every 8 h for
24 h; serial cardiac enzymes were repeated any time a patient experi-
enced recurrent ischemic symptoms lasting N30 min. A complete
blood count was obtained on admission and repeated daily for three
days. Following discharge, follow up was performed at 30 days and at
6 months.
2.3. Measurement of platelet reactivity
Platelet function testing was performed at baseline, at 1, 2, 4, 6, 24,
and 48h after the initial LD.We used the point of care device, VerifyNow
(Accumetrics) tomeasure platelet function. The VerifyNow P2Y12 assay
uses adenosine diphosphate to induce platelet aggregation, and mea-
sures the increase in light transmittance as P2Y12 reaction units
(PRU). A higher PRU result indicates greater P2Y12-mediated platelet
reactivity [17,18]. Recent studies have identiﬁed a PRU cutoff of N208
as the level for HPR that provides themaximal sensitivity and speciﬁcityfor the prediction of major adverse cardiovascular events after PCI [19,
20].
We also measured the response to 160 mg chewable aspirin given
before the PCI with the VerifyNow Aspirin Assay. The amount of throm-
boxane A2-mediated activation of glycoprotein IIb/IIIa receptors in-
volved in platelet aggregation is reported in Aspirin Reaction Units
(ARU). We used an ARU N550 to identify aspirin poor responders, as
suggested by others [21,22].
2.4. Endpoints
The main objective of this study was to evaluate the extent of plate-
let reactivity between the two high LDs of clopidogrel in STEMI patients
referred for primary PCI with the VerifyNow P2Y12 assay. The primary
endpoint was deﬁned as the proportion of patients with HPRmeasured
at 24 h deﬁned as a PRU N208. We initially had chosen a cutoff of 230;
however studies emerged identifying the 208 cutoff as beingmore accu-
rate at predictingmajor adverse cardiovascular events [19,20]. The deci-
sion to change the cutoff to 208 for the primary endpoint was reached
before analysis of the data, and it was decided to use the 230 cutoff as
a secondary endpoint.
Secondary endpoints also included in-hospital death, reinfarction,
stroke, and bleeding. Episodes of bleeding were deﬁned as major or
minor according to the TIMI classiﬁcation [23]. Stent thrombosiswas re-
ported according to the ARC deﬁnition [24].
Physicians involved with the care of the patient were blinded to the
platelet test results and an independent committee adjudicated clinical
events.
2.5. Statistical analysis
At the time of the trial design there was limited data on the pharma-
codynamics of clopidogrel in STEMI patients referred for primary PCI
who were loaded with the antiplatelet agent prior to cardiac catheteri-
zation. In this exploratory study,we chose a sample size of 50 patients in
total expecting approximately 25 patients in each group. Subject ran-
domization numbers were generated by the study coordinating center
and included balanced blocks. Sets of patient numbers and associated
treatment(s) were provided in sealed opaque envelopes. The patient
randomization numbers/envelopes were allocated sequentially in the
order in which the subjects were enrolled.
Descriptive statistics were used to evaluate the comparability of pa-
tients randomized to either group. Categorical variables were expressed
as proportions, and continuous variables as means and standard devia-
tions or asmedians and interquartile ranges as appropriate. All analyses
on the primary endpoint and its components were performed on an in-
tention-to-treat basis.
Normally distributed continuous variables were analyzed using the
student's t-test and non-normally distributed continuous variables
were analyzed using Mann Whitney U test. Categorical variables were
compared using a chi-square or Fisher's exact test (when appropriate)
at each time point. P values for an overall dose effect and p values for
trends over timewere obtained using a generalized estimating equation
approach for dichotomous variables; and a mixed model approach for
continuous variables. A p value ≤0.05was considered statistically signif-
icant. Analyses were performed using SAS (version 9.2, SAS Institute
Inc., Cary, NC, USA). The institutional review board approved the proto-
col; and all patients provided informed consent.
3. Results
3.1. Patients
We randomly assigned a total of 54 patients to a clopidogrel high LD:
27 patients received single 600 mg LD and 27 patients received a
600/600 mg double LD, between March 2009 and December 2010.
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two groups were relatively well matched in baseline characteristics.
There was no difference between the two groups in the proportion of
patients undergoing PCI and all patients treated with PCI received
stents. Coronary ﬂow at baseline and after PCI was not signiﬁcantly dif-
ferent between the two groups. The peak creatine kinase was 1448 ±
1137 U/L in the single 600 mg LD group and was 2004 ± 1826 U/L in
the 600/600 mg double LD group, p-0.19.Fig. 1. Proportion of patients with high platelet reactivity following clopidogrel loading
dose. The ﬁgure depicts the proportion of patients with high platelet reactivity (HPR), de-
ﬁned as PRU N 208, shown at each time point for the 600mg clopidogrel loading dose (LD)
and 600/600 mg double LD strategies. Data concerning the primary endpoint, deﬁned as
the proportion of patients with HPR at 24 h following the LD, was available in 50 of the
54 patients; there was no signiﬁcant difference between the two LD strategies, p = 0.23.
Furthermore, none of the proportions were observed to be statistically different across
doses at any time point. For each LD there was a signiﬁcant decrease over time in the pro-
portion of patients with HPR, p b 0.001; however there was no overall LD effect, p= 0.07.3.2. Platelet reactivity
The results regarding the primary endpoint are shown in Fig. 1. The
proportion of patients with HPR at 24 h was recorded in 11 (44.0%) pa-
tients assigned to the 600mg LD and in 6 (24.0%) of patients assigned to
600/600 mg LD, p = 0.23. There was no difference in HPR at any of the
time points measured between the different LDs between the two
groups. Using a PRU cutoff of 230, the proportion of patients with HPR
at 24 h was 40.0% amongst patients with the 600 mg LD and 24.0%
with the 600/600 mg LD, p = 0.36. At 24 h following the initial LD, the
proportion of all study patients with PRUs N208 was 34.0% and with
PRUs N230 was 32.0%.
The mean PRUs measured at the various time points for the two
groups are shown in Fig. 2. There was no signiﬁcant difference in
mean PRU between each LD at any time point measured between the
two groups. The mean PRU at 24 h was 191 ± 102 in the 600 mg
group and 152 ± 94 in the 600/600 mg group, p = 016.Table 1
Baseline characteristics.
Clopidogrel LD:
600 mg
(n= 27)
Clopidogrel LD:
600/600 mg
(n= 27)
P value
Age, year 59.9 ± 13.2 62.8 ± 13.0 0.42
Male sex, no. (%) 26 (96.2) 21 (77.8) 0.10
Hypertension, no. (%) 6 (22.2) 12 (44.4) 0.15
Diabetes mellitus, no. (%) 3 (11.1) 1 (3.7) 0.61
Current smoker, no. (%) 11(40.7) 10 (38.5) 1.00
History of hyperlipidimia,
no. (%)
8 (30.8) 11 (40.7) 0.57
Previous myocardial infarction, no. (%) 2 (7.4) 2(7.4) 1.00
Previous stroke, no. (%) 2 (7.4) 1 (3.7) 1.00
Previous angioplasty, no. (%) 1(3.7) 2(7.4) 1.00
Previous bypass surgery, no. (%) 0 (0) 2 (7.4) 0.25
Anterior myocardial infarction, no. (%) 15 (55.6) 10 (37.0) 0.28
Heart rate, beats per minute 78.0 ± 20.2 79.9 ± 17.8 0.72
Systolic blood pressure, mm Hg 136.1 ± 18.5 139.5 ± 27.0 0.59
Diastolic blood pressure, mm Hg 82.4 ± 13.2 79.6 ± 17.4 0.51
Killip class, no. (%) 1.00
I 23 (85.2) 22 (81.5)
II-III 4 (14.8) 5 (18.5)
Direct ﬁeld transfer, no. (%) 11 (40.7) 12 (40.4) 1.00
Body mass index, kg/m2 28.4 ± 3.7 27.4 ± 3.0 0.27
Creatinine clearance, ml/min 96.2 ± 38.2 92.7 ± 39.8 0.68
PCI performed 26 (96.3) 25 (92.6) 1.00
Door to balloon time,
median (IQR), min
72 (38–94) 63 (39–83) 0.03
Multivessel disease, no. (%) 13 (48.1) 12 (44.4) 1.00
Coronary ﬂow at baseline 0.31
TIMI grade 0, no. (%) 20 (74.1) 17 (71.2)
TIMI grade 1, no. (%) 0 (0) 3 (12.0)
TIMI grade 2, no. (%) 2 (7.4) 1 (4.0)
TIMI grade 3, no. (%) 5 (18.5) 4 (16.0)
Coronary ﬂow after procedure 0.60
TIMI grade 2, no. (%) 1 (3.7) 2 (8.0)
TIMI grade 3, no. (%) 26 (96.3) 23 (92.0)
Plus-minus values are means ± SD.
PCI=percutaneous coronary intervention. TIMI=Thrombolysis InMyocardial Infarction.3.3. Response to aspirin
Poor response to aspirin, i.e. ARU N550, was documented in 1/51
(2.0%) of patients at 4 h and in 4/51 (7.8%) of patients at 24 h.3.4. Clinical outcomes
During thehospital admissionnoneof thepatients died or experienced
a stroke. One patient in the 600/600mg LD group experienced a subacute
stent thrombosis conﬁrmed by coronary angiography and required repeat
intervention. This event was also adjudicated as a reinfarction. TIMImajor
bleeding occurred in 1 patient in the 600/600mg LDgroupbut occurred in
none in the 600mg LD group; TIMI minor bleeding occurred in 4 patients
(14.8%) in the 600 mg LD group and 2 (7.4%) in 600/600 mg group, p =
0.43. At the 180-day follow-up, there was one patient assigned to the
600/600mg groupwho had died. There were no additional events during
the follow-up period.Fig. 2.Mean platelet reaction unit (PRU) at each time point. The ﬁgure depicts the mean
PRU and standard deviation plotted at each time point for the respective loading dose
(LD). Within each group, none of the means were observed to be statistically different
across doses at any time point. For each LD, there was a signiﬁcant decrease in the mean
over time, p b 0.001; however there was no overall LD effect, p = 0.29.
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Our study indicates that a signiﬁcant proportion of STEMI patients
referred for primary PCI have HPR at 24 h following a single 600 mg
or a double 600/600 mg clopidogrel LD strategy. These results may
have implications regarding the risk of acute stent thrombosis in
STEMI patients treated with clopidogrel.
The relationship betweenHPR and ischemic events followingPCI has
previously been established [1,4,25,26]. A recent meta-analysis using
data from 3059 patients treated with PCI showed that HPR was associ-
ated with clinical events such as death, myocardial infarction, and
stent thrombosis at long term follow-up [27]. Moreover Park et al. re-
cently reported an adjusted hazard ratio of 3.5 for mortality at log-
term in acute coronary syndrome patients undergoing PCI with HPR
as compared to those without HPR [28]. However, despite this link
between HPR and clinical events, recent trials have not been able to
demonstrate a clinical beneﬁt of routine platelet function monitoring
with adjustment of antiplatelet therapy in patients undergoing non-
emergent coronary stenting [29–31]. More importantly, these studies
excluded patients treated with primary PCI and were not designed to
evaluate the impact of HPR early in the management of these patients.
The effect of clopidogrel LDs on platelet reactivity has been evaluat-
ed mostly in relatively stable patients. The Clopidogrel Loading with
Eptiﬁbatide to Arrest the Reactivity of Platelets Study (CLEAR PLATE-
LETS) evaluated 120 patients undergoing elective stenting and conclud-
ed that in the absence of a glycoprotein IIb/IIIa inhibitor, a 600 mg LD
provided better platelet inhibition than a 300 mg LD at all time points
measured within 24 h [32]. Similarly, the Assessment of the Best Load-
ing Dose of Clopidogrel to Blunt Platelet Activation, Inﬂammation and
Ongoing Necrosis (ALBION) trial reported on 103 non-STEMI patients
that 600 mg and 900 mg LDs provide faster onset of platelet inhibition
and a higher inhibition of platelet activity plateau during the ﬁrst 24 h
than a 300mg LD; a 900mg LD appeared to induce a greater antiplatelet
effect than a 600mgLD,when comparedwith the300mg LD [9]. Finally,
the cloPidogREl PlAtelet Inhibition Regimens (PREPAIR) study com-
pared the level of platelet inhibition achieved in 148 patients undergo-
ing elective PCI randomly assigned to one of 3 LDs strategies: 300 mg
the day before the procedure; or 600mg themorning of the procedure;
or 600mg the day before and 600mg themorning of the procedure. The
600 mg double LD achieved greater platelet inhibition as measured at
the time of angiography than the two conventional single LD [13].
Thus, in stable patients, higher clopidogrel LDs appears to result in
greater platelet inhibition.
In STEMI patients, data regarding the pharmacokinetics and phar-
macodynamics of clopidogrel remain scarce. Catecholamine release is
generally higher in STEMI patients as compared to normal volunteers
or patientswith relatively stable coronary disease, and thismay be asso-
ciated with HPR. Furthermore, a lower cardiac output may alter absorp-
tion of clopidogrel and reduce perfusion to the liver where the drug is
converted to the active thiol metabolite. A multivariable analysis
assessing 833 patients pretreated with 600 mg clopidogrel before PCI,
found that the presence of STEMI was an independent predictor of HPR
as measured by a vasodilator phosphoprotein index ≥50% at 6–12 h
following the LD [15]. Matetzky et al. evaluated 60 STEMI patients pre-
scribed a 300 mg clopidogrel LD on completion of primary PCI, followed
by a 75 mg daily maintenance dose, and reported that up to 25% had
HPR by light transmission aggregometry at 6 days after the procedure [5].
It has been suggested that a limit on intestinal absorption of
clopidogrel may inﬂuence the extent of platelet inhibition initially
achieved following a LD [10]. One small trial compared the pharmacoki-
netic response of a clopidogrel 600mgLD in 11 STEMI patients and in 10
healthy volunteers; bioavailability was signiﬁcantly impaired in the
STEMI patients and this was associated with a strong correlation be-
tween the reduction in platelet aggregation and the maximal plasma
concentration of the active metabolite [16]. Although we did not
measure plasma clopidogrel metabolites, these results suggest thepossibility that altered and limited intestinal absorption of the drug
may have contributed to the pharmacodynamic proﬁle seen in our
patients.
Our results may provide an explanation for the higher rates of early
stent thrombosis seen in STEMI patients treatedwith bivalirudinmono-
therapy as reported in the Harmonizing Outcomes with Revasculariza-
tion and Stents (HORIZONS-AMI) trial [33]. Although a 600 mg LD of
clopidogrel as compared to a 300mg LDmay have reduced stent throm-
bosis in these patients, it was suggested thatmore potent oral antiplate-
let agents with faster kinetics may prove beneﬁcial [34]. The TRITON–
TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Op-
timizing Platelet Inhibition with Prasugrel–Thrombolysis In Myocardial
Infarction 38) trial, reported on 3354 STEMI patients that prasugrel as
compared to clopidogrel resulted in a signiﬁcant reduction in cardiovas-
cular death, reinfarction, or stroke at 15months [35]. Ticagrelor, a novel
reversibly binding oral P2Y12 receptor antagonist, also provides faster,
greater, and more consistent inhibition of platelet function than
clopidogrel. In the Platelet Inhibition and Patient Outcomes (PLATO)
trial STEMI substudy involving 7544 patients, ticagrelor as compared to
clopidogrel reduced total mortality, reinfarction, and stent thrombosis
at 12months [36]. Hence new andmore potent P2Y12-ADP receptor an-
tagonistsmaybepreferred in patients treatedwith primary PCI, especial-
ly when glycoprotein IIb/IIIa platelet receptor inhibitors are not used.
Our study indicates that a signiﬁcant proportion of STEMI patients
retain HPR at 24 h despite high clopidogrel LDs: 44% with a single
600 mg LD and 24% with a 600/600 mg double LD. Our results are in
sharp contrast to those reported recently in STEMI patients treated
with novel P2Y12 antiplatelet agents. Alexopoulos et al. randomized
55 STEMI patients to receive a standard LD of prasugrel or ticagrelor
and found that none of the patients treated with ticagrelor and b5% of
the patients treated with prasugrel had a PRU N208 at the 24 h time
point [37]. Similarly, the Rapid Activity of Platelet Inhibitor Drugs
(RAPID) Primary PCI Study assessed HPR after a standard oral antiplate-
let agent LD in 25 patients assigned to prasugrel and 25 patients
assigned to ticagrelor; the proportion of patients with HPR by 12 h
was virtually nil with either agent [38].
Finally bridgingwith an intravenous P2Y12 inhibitor could eliminate
the window of vulnerability for stent thrombosis following an oral
clopidogrel LD. Indeed, the Cangrelor versus Standard Therapy to
Achieve Optimal Management of Platelet Inhibition (CHAMPION)
PHOENIX study has recently conﬁrmed that Cangrelor, a rapidly acting,
potent, and quickly reversible intravenous ADP-receptor antagonist,
signiﬁcantly reduced ischemic events, including stent thrombosis,
with no signiﬁcant increase in severe bleeding in patients undergoing
elective or urgent PCI [39].
Our study is not without limitations. First, the study could have been
further enhanced with serial measurements of clopidogrel metabolites.
With the current data, we are unable to comment if decreased absorption
or impairedmetabolismof the drug resulted in its delay in onset of action.
Secondly, the sample size was relatively small and it is possible that we
lacked power to detect statistically signiﬁcant differences between the
two clopidogrel LDs. Regardless, in our pilot study, the high platelet reac-
tivity recorded at 24 h in 24% of patients assigned to a 600/600mgdouble
LD of clopidogrel, remains a concern, given the far superior results which
can be achieved with the novel oral antiplatelet agents [38].
In conclusion, we found that HPR persisted at 24 h in a signiﬁcant
proportion of patients referred for primary PCI regardless of two
clopidogrel high LD strategies. These results infer that there may be an
insurmountable pharmacodynamic plateau for many STEMI patients
managed with clopidogrel, and that other antiplatelet strategies are
needed to reduce the likelihood of early stent thrombosis.
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